The Roche cervical cancer portfolio provides three clinically validated tests to help identify women at risk and improve detection and confirmation of high-grade disease in a single round of screening. The powerful combination of these tests supports healthcare professionals in making decisions for their patients with confidence.
cobas® HPV test
Screen with the cobas® HPV test, the first clinically validated, FDA-approved, CE-IVD marked HPV DNA test for for all cervical screening indications: primary screening, ASC-US triage and co-testing. Screening with HPV DNA can identify women at risk for cervical cancer. cobas® HPV simultaneously provides pooled results on known high-risk HPV genotypes, and individual results on the two highest-risk genotypes, HPV 16 and HPV 18, giving three results in one from a single sample.
Manage with CINtec®PLUS Cytology, the only test that uses dual-biomarker technology to simultaneously detect p16 and Ki-67 to provide a strong indicator of the presence of transforming HPV infection.
*CINtec®PLUS Cytology is a CE/IVD product, approved for clinical use. CINtec®PLUS Cytology is not available for this use in the United States. Check with your local Roche representative for the availability of products in your region and the applicable intended use.
Diagnose with CINtec® Histology – Enhances identification of occult cervical lesions that may be missed by H&E or morphologic interpretation alone. The CINtec® Histology test is the only clinically validated test that uses advanced p16 biomarker technology to confirm the presence or absence of cervical lesions due to transforming HPV infections.